Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Table 3 Multivariate analysis of factors predicting recurrence-free survival

Variable	Recurrence-free survival
Variable	HR	95% CI	p
Model A
Primary tumor (T) (III/IV vs I/II)	2.404	1.537–3.759	< 0.001
Lymph nodes metastasis (N) (Yes vs No)	1.451	0.944–2.229	0.090
TNM Stage (III/IV vs I/II)	1.025	0.589–1.783	0.931
CD44 (High vs Low)	1.476	1.062–2.051	0.020
Model B
Primary tumor (T) (III/IV vs I/II)	2.341	1.482–3.697	< 0.001
Lymph nodes metastasis (N) (Yes vs No)	1.368	0.880–2.126	0.164
TNM Stage (III/IV vs I/II)	1.024	0.579–1.871	0.934
CD44v6 (Pos. vs Neg.)	1.350	0.975–1.871	0.071
Model C
Primary tumor (T) (III/IV vs I/II)	2.665	1.686–4.212	< 0.001
Lymph nodes metastasis (N) (Yes vs No)	1.441	0.934–2.223	0.098
TNM Stage (III/IV vs I/II)	0.933	0.528–1.649	0.810
CD44v8-10 (Pos. vs Neg.)	1.491	1.092–2.036	0.012

TNM size of primary tumor-node metastasis-distant metastasis, CD44 cluster of differentiation 44, CD44v CD44 variant, Neg negative expression, Pos positive expression

ISSN: 1479-5876